Canada markets open in 8 hours 39 minutes

Insulet Corporation (GOV.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
161.95+1.05 (+0.65%)
At close: 09:55PM CEST
Full screen
Previous Close160.90
Open160.35
Bid0.00 x 12100
Ask0.00 x 11600
Day's Range160.35 - 165.50
52 Week Range119.30 - 304.90
Volume6
Avg. Volume1
Market Cap11.383B
Beta (5Y Monthly)1.00
PE Ratio (TTM)58.89
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    Insulet to Announce First Quarter 2024 Financial Results on May 9, 2024

    ACTON, Mass., April 03, 2024--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the first quarter of 2024 on May 9, 2024 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time).

  • Business Wire

    Insulet Appoints Ana Maria Chadwick as Chief Financial Officer

    ACTON, Mass., March 20, 2024--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that Ana Maria Chadwick has been appointed Executive Vice President, Chief Financial Officer and Treasurer, effective April 22, 2024. Today’s announcement concludes an extensive search process conducted by the Company.

  • Business Wire

    Insulet’s Randomized Controlled Trial (OP5-003) Demonstrates Omnipod® 5 Automated Insulin Delivery System is Superior to Pump Therapy

    ACTON, Mass., March 08, 2024--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today presented positive results from its first randomized controlled trial (RCT) showing improved glycemic and patient-reported outcomes in type 1 diabetes with the Omnipod 5 Automated Insulin Delivery System (Omnipod 5). The OP5-003 Trial results were presented at the 17th International Conference on Advanced Techn